Sanofi exec to head up LEO’s translational R&D—Chutes & Ladders by Conor Hale Friday, February 1, 2019 Ex-Sanofi exec to head up translational medicine at LEO Pharma; Calico brings on Amgen R&D leader to head early development; and Lonza CEO to retire.
Calico nets Amgen’s translational R&D head to lead drug research by Conor Hale Thursday, January 31, 2019 Amgen’s head of translational medicine, Aarif Khakoo, M.D., is making the jump to Calico Life Sciences to head up drug development.
AbbVie, Calico renew their aging research collaboration with $1B by Conor Hale Tuesday, June 26, 2018 AbbVie and Calico reupped their $1.5 billion collaboration on age-related diseases, with a new billion-dollar commitment split between the two.
C4 Therapeutics promotes chief science officer to CEO by Conor Hale Thursday, May 3, 2018 Chief Scientific Officer Andrew Phillips was named CEO of C4 Therapeutics, a 2016 Fierce 15 winner.
Koller, A-list backers unite to create machine learning startup by Nick Paul Taylor Wednesday, May 2, 2018 Daphne Koller, an ex-Calico AI expert, plans to enlist data and machine learning to address shortcomings in drug discovery and development.
Chutes & Ladders—Parexel co-founder ends 35-year run as CEO by Angus Liu Friday, March 9, 2018 Jamie Macdonald succeeds Joseph von Rickenbach as Parexel CEO, Roche promotes William Pao to replace John Reed as pRED head, Moderna loses vaccines head.
Calico loses its second exec in 4 months as Daphne Koller quits by Amirah Al Idrus Friday, March 2, 2018 Machine learning veteran Daphne Koller is leaving less than two years after joining Calico as chief computing officer.
Chutes & Ladders—GlaxoSmithKline CSO Vallance out, Hal Barron in by Angus Liu Friday, November 10, 2017 Hal Barron replaces Patrick Vallance as GSK CSO, Biogen lured Merck exec to head global marketing and Celgene vet Pehl lands at Immunomedics.
Roche, Calico vet Hal Barron takes GSK R&D hot seat, as Vallance out by Ben Adams Wednesday, November 8, 2017 Former Roche and Calico vet Hal Barron has become the new CSO and research chief at GlaxoSmithKline amid a shake-up from its new CEO Emma Walmsley.
Longevity Fund raises cash to back anti-aging startups by Nick Paul Taylor Wednesday, August 23, 2017 The financing gives Laura Deming, who started work on the fund before turning 18, $22 million to invest in companies working on age-related diseases.